AC
NBIX icon

Armistice Capital’s Neurocrine Biosciences NBIX Stock Holding History

Armistice Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.3M Sell
535,838
-188,162
-26% -$27.9M 1.1% 9
2026
Q1 		$95.4M Sell
724,000
-96,240
-12% -$12.8M 1.7% 9
2025
Q4 		$116M Buy
820,240
+123,218
+18% +$17.9M 1.38% 8
2025
Q3 		$97.8M Buy
697,022
+20,998
+3% +$2.85M 1.45% 7
2025
Q2 		$85M Sell
676,024
-324,166
-32% -$37.2M 1.47% 7
2025
Q1 		$111M Buy
1,000,190
+108,190
+12% +$13.7M 1.66% 6
2024
Q4 		$122M Buy
892,000
+710,619
+392% +$87.9M 1.66% 7
2024
Q3 		$20.9M Sell
181,381
-797,107
-81% -$109M 0.33% 57
2024
Q2 		$135M Sell
978,488
-45,251
-4% -$6.21M 1.69% 5
2024
Q1 		$141M Sell
1,023,739
-24,261
-2% -$3.31M 1.87% 4
2023
Q4 		$138M Sell
1,048,000
-168,365
-14% -$19.4M 1.89% 4
2023
Q3 		$137M Sell
1,216,365
-433,635
-26% -$45.7M 2.1% 5
2023
Q2 		$156M Buy
1,650,000
+58,000
+4% +$5.67M 2.25% 3
2023
Q1 		$161M Buy
1,592,000
+692,000
+77% +$72M 2.32% 3
2022
Q4 		$107M Sell
900,000
-424,000
-32% -$49.7M 1.88% 10
2022
Q3 		$141M Hold
1,324,000
– – 2.44% 7
2022
Q2 		$129M Buy
1,324,000
+674,000
+104% +$62.2M 2.25% 7
2022
Q1 		$60.9M Buy
+650,000
New +$55.1M 1.18% 25

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Armistice Capital's NBIX Position: Q2 2026 in Review

Armistice Capital reduced its Neurocrine Biosciences (NBIX) stake by 26% in Q2 2026, selling an estimated $27.9M and leaving 535,838 shares worth $90.3M. The position accounts for 1.1% of the portfolio, ranked #9.

Armistice Capital first reported a position in NBIX in Q1 2022 and has held it in 18 quarters since. The position peaked at $161M in Q1 2023. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Armistice Capital held 535,838 shares of Neurocrine Biosciences worth $90.3M as of Q2 2026.
  • Armistice Capital sold 188,162 Neurocrine Biosciences shares in Q2 2026, an estimated $27.9M.
  • Neurocrine Biosciences made up 1.1% of Armistice Capital's portfolio in Q2 2026, its #9 holding.
  • Armistice Capital first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 18 quarters since.
  • Armistice Capital's Neurocrine Biosciences position peaked at $161M in Q1 2023.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.